Ocular, Vascular, and Genetic Findings in AMD Patients

Explorational observation of ocular, vascular, and genetic findings in patients diagnosed with AMD

Inclusion criteria

• At least 55 years of age at the time of consent
• Able to understand and provide written informed consent
• Sufficiently clear ocular media, adequate pupillary dilation, and adequate fixation to permit quality fundus imaging
• Able to cooperate with ophthalmic visual function testing and anatomic assessments
• Diagnosed with late-stage AMD in at least one eye. (if both eyes of an eligible subject meet inclusion criterion, the more advanced eye will receive primary eye assignment)
• Willing to have protocol specified genetic testing
• Willing to have head coil MRI/A (with contrast if deemed necessary)

Exclusion criteria

Ocular

• History of any retinal disease other than AMD in either eye
• Spherical equivalent refractive error demonstrating >6 diopters of myopia or an axial length >26 mm in the study eye
• History of vitrectomy in the study eye
• Any intraocular surgery (including lens replacement surgery) in the study eye, within 90 days of enrollment
• History of endophthalmitis
• Trabeculectomy or aqueous shunt or valve in the study eye
• Aphakia or absence of the posterior capsule in the study eye (Note: Previous violation of the posterior capsule is also excluded unless it occurred as a result of yttrium aluminum garnet [YAG] laser posterior capsulotomy in association with prior posterior chamber intraocular lens implantation and at least 90 days prior to enrollment)
• Presence of advanced guttae or visually significant keratopathy that would cause scattering of light or alter visual function in the study eye
• History of idiopathic or autoimmune-associated uveitis in either eye
• Active inflammation or infection, including conjunctivitis, keratitis, or scleritis in either eye
• GA secondary to a condition other than AMD (e.g., Stargardt's disease, cone rod dystrophy, or toxic maculopathies such as Plaquenil maculopathy) in either eye

Non-Ocular

• Use of any investigational product or investigational medical device (i.e., not approved by FDA for the specific use) within 90 days prior to screening or anticipated use during the study
• Women of childbearing potential who are pregnant or unwilling to use effective contraception for the duration of the study
• Acute or serious illness, in the opinion of the site investigator
• History of kidney failure or gadolinium toxicity